| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Shock | 15 | 2025 | 32 | 5.170 |
Why?
|
| Vasoconstrictor Agents | 22 | 2025 | 62 | 5.160 |
Why?
|
| Respiratory Insufficiency | 8 | 2023 | 59 | 4.130 |
Why?
|
| Hypotension | 14 | 2025 | 48 | 4.060 |
Why?
|
| Angiotensin II | 16 | 2025 | 245 | 3.990 |
Why?
|
| Postoperative Complications | 14 | 2023 | 828 | 3.270 |
Why?
|
| Monitoring, Physiologic | 10 | 2025 | 77 | 3.230 |
Why?
|
| Shock, Septic | 9 | 2024 | 26 | 3.210 |
Why?
|
| Critical Illness | 10 | 2024 | 84 | 3.180 |
Why?
|
| Analgesics, Opioid | 10 | 2021 | 252 | 3.140 |
Why?
|
| Critical Care | 9 | 2025 | 109 | 2.220 |
Why?
|
| Surgical Procedures, Operative | 9 | 2021 | 78 | 2.150 |
Why?
|
| Humans | 109 | 2025 | 32822 | 2.130 |
Why?
|
| Heart Injuries | 4 | 2021 | 9 | 1.990 |
Why?
|
| Intensive Care Units | 12 | 2025 | 115 | 1.900 |
Why?
|
| Postoperative Care | 4 | 2020 | 78 | 1.870 |
Why?
|
| Oximetry | 5 | 2021 | 31 | 1.690 |
Why?
|
| Hemodynamics | 6 | 2025 | 162 | 1.510 |
Why?
|
| Vital Signs | 2 | 2025 | 10 | 1.510 |
Why?
|
| Monitoring, Intraoperative | 7 | 2025 | 44 | 1.480 |
Why?
|
| Blood Pressure | 9 | 2025 | 862 | 1.450 |
Why?
|
| Norepinephrine | 8 | 2024 | 75 | 1.440 |
Why?
|
| Capnography | 5 | 2022 | 9 | 1.340 |
Why?
|
| Pain, Postoperative | 6 | 2020 | 193 | 1.320 |
Why?
|
| Physical Examination | 2 | 2023 | 89 | 1.310 |
Why?
|
| Hospital Mortality | 7 | 2025 | 205 | 1.240 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 63 | 1.220 |
Why?
|
| Propensity Score | 3 | 2025 | 48 | 1.200 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 98 | 1.150 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 102 | 1.150 |
Why?
|
| Sepsis | 5 | 2024 | 166 | 1.130 |
Why?
|
| Middle Aged | 37 | 2025 | 12133 | 1.060 |
Why?
|
| Atrial Fibrillation | 4 | 2020 | 391 | 1.040 |
Why?
|
| Lactic Acid | 3 | 2025 | 58 | 1.010 |
Why?
|
| Aged | 28 | 2025 | 10544 | 1.010 |
Why?
|
| Anesthesiology | 3 | 2022 | 48 | 0.980 |
Why?
|
| Male | 48 | 2025 | 19658 | 0.980 |
Why?
|
| Female | 42 | 2025 | 20275 | 0.950 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 105 | 0.940 |
Why?
|
| Patient Discharge | 3 | 2025 | 204 | 0.920 |
Why?
|
| Anesthesia | 3 | 2022 | 64 | 0.900 |
Why?
|
| Resuscitation | 2 | 2023 | 67 | 0.840 |
Why?
|
| Renin-Angiotensin System | 3 | 2024 | 178 | 0.820 |
Why?
|
| Analgesia, Patient-Controlled | 3 | 2020 | 19 | 0.800 |
Why?
|
| Goals | 1 | 2023 | 35 | 0.790 |
Why?
|
| Hypovolemia | 1 | 2023 | 3 | 0.790 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2022 | 57 | 0.770 |
Why?
|
| Prospective Studies | 12 | 2023 | 2329 | 0.760 |
Why?
|
| Hospitalization | 4 | 2025 | 488 | 0.730 |
Why?
|
| Retrospective Studies | 14 | 2023 | 3705 | 0.720 |
Why?
|
| Risk Assessment | 9 | 2021 | 1461 | 0.720 |
Why?
|
| Adult | 27 | 2025 | 9570 | 0.720 |
Why?
|
| Vasodilation | 2 | 2019 | 92 | 0.700 |
Why?
|
| Treatment Outcome | 13 | 2025 | 3441 | 0.670 |
Why?
|
| Microcirculation | 1 | 2021 | 64 | 0.670 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2020 | 1 | 0.660 |
Why?
|
| Spiro Compounds | 1 | 2020 | 2 | 0.660 |
Why?
|
| Respiratory Rate | 4 | 2022 | 13 | 0.660 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 4034 | 0.660 |
Why?
|
| Thiophenes | 1 | 2020 | 23 | 0.650 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 34 | 0.640 |
Why?
|
| Morphine | 1 | 2020 | 47 | 0.640 |
Why?
|
| Patients' Rooms | 1 | 2019 | 3 | 0.610 |
Why?
|
| Carbon Dioxide | 2 | 2018 | 39 | 0.570 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 80 | 0.560 |
Why?
|
| Renin | 4 | 2024 | 109 | 0.560 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 181 | 0.550 |
Why?
|
| Risk Factors | 13 | 2021 | 3976 | 0.540 |
Why?
|
| Intubation, Intratracheal | 3 | 2021 | 74 | 0.540 |
Why?
|
| Vasopressins | 4 | 2023 | 17 | 0.530 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 98 | 0.510 |
Why?
|
| Intraoperative Complications | 3 | 2023 | 59 | 0.510 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 252 | 0.500 |
Why?
|
| Catecholamines | 4 | 2020 | 18 | 0.490 |
Why?
|
| Analgesia, Epidural | 1 | 2016 | 50 | 0.490 |
Why?
|
| Anesthetics, Local | 1 | 2016 | 81 | 0.480 |
Why?
|
| Inpatients | 3 | 2021 | 90 | 0.480 |
Why?
|
| Cohort Studies | 7 | 2023 | 1844 | 0.480 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2016 | 91 | 0.460 |
Why?
|
| Pulmonary Veins | 1 | 2014 | 19 | 0.440 |
Why?
|
| Vascular Malformations | 1 | 2014 | 11 | 0.440 |
Why?
|
| Incidence | 5 | 2020 | 1239 | 0.430 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 61 | 0.420 |
Why?
|
| Anti-Infective Agents | 2 | 2017 | 44 | 0.390 |
Why?
|
| Vasoplegia | 2 | 2024 | 2 | 0.390 |
Why?
|
| Cardiac Output | 2 | 2025 | 34 | 0.380 |
Why?
|
| Blood Pressure Determination | 4 | 2024 | 102 | 0.370 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 98 | 0.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 136 | 0.350 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 11 | 0.340 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 162 | 0.330 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2021 | 81 | 0.310 |
Why?
|
| Postoperative Period | 2 | 2020 | 99 | 0.300 |
Why?
|
| Heart Arrest | 2 | 2019 | 40 | 0.300 |
Why?
|
| Double-Blind Method | 4 | 2019 | 525 | 0.290 |
Why?
|
| Physicians | 1 | 2021 | 165 | 0.290 |
Why?
|
| Ureteral Obstruction | 2 | 2018 | 28 | 0.280 |
Why?
|
| Time Factors | 8 | 2021 | 2185 | 0.270 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 40 | 0.270 |
Why?
|
| Preoperative Care | 2 | 2020 | 123 | 0.270 |
Why?
|
| Pain Measurement | 2 | 2020 | 356 | 0.260 |
Why?
|
| Prognosis | 4 | 2020 | 1545 | 0.250 |
Why?
|
| Oxygen | 3 | 2016 | 144 | 0.250 |
Why?
|
| Bariatric Surgery | 3 | 2015 | 25 | 0.250 |
Why?
|
| United States | 6 | 2023 | 4109 | 0.240 |
Why?
|
| Scopolamine | 2 | 2016 | 5 | 0.240 |
Why?
|
| Pulmonary Alveolar Proteinosis | 2 | 2016 | 2 | 0.240 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2016 | 14 | 0.240 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2016 | 8 | 0.240 |
Why?
|
| Attitude of Health Personnel | 2 | 2025 | 188 | 0.240 |
Why?
|
| Depressive Disorder, Major | 2 | 2016 | 41 | 0.230 |
Why?
|
| Acetates | 1 | 2025 | 12 | 0.220 |
Why?
|
| Fluid Therapy | 1 | 2025 | 24 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 532 | 0.220 |
Why?
|
| Angiotensinogen | 1 | 2024 | 59 | 0.220 |
Why?
|
| Aspirin | 2 | 2022 | 62 | 0.210 |
Why?
|
| Catheterization, Peripheral | 1 | 2024 | 30 | 0.210 |
Why?
|
| Telemedicine | 1 | 2025 | 117 | 0.210 |
Why?
|
| Electronics | 1 | 2023 | 14 | 0.210 |
Why?
|
| Nitroglycerin | 1 | 2003 | 11 | 0.200 |
Why?
|
| Intestinal Diseases | 1 | 2003 | 16 | 0.200 |
Why?
|
| Vasodilator Agents | 1 | 2003 | 59 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2022 | 369 | 0.200 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2023 | 10 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 949 | 0.200 |
Why?
|
| Peptide Hormones | 1 | 2023 | 10 | 0.200 |
Why?
|
| Reperfusion Injury | 1 | 2003 | 58 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 289 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 34 | 0.190 |
Why?
|
| Virus Diseases | 1 | 2022 | 22 | 0.190 |
Why?
|
| Patient Readmission | 2 | 2021 | 134 | 0.190 |
Why?
|
| Medicare | 1 | 2023 | 213 | 0.180 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 576 | 0.180 |
Why?
|
| Algorithms | 2 | 2025 | 511 | 0.180 |
Why?
|
| Europe | 2 | 2018 | 83 | 0.180 |
Why?
|
| Data Collection | 1 | 2022 | 185 | 0.180 |
Why?
|
| Propofol | 2 | 2012 | 20 | 0.180 |
Why?
|
| Motivation | 1 | 2022 | 110 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 888 | 0.170 |
Why?
|
| Endarterectomy | 1 | 2021 | 6 | 0.170 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 15 | 0.170 |
Why?
|
| Delphi Technique | 1 | 2021 | 43 | 0.170 |
Why?
|
| Lung Transplantation | 1 | 2021 | 14 | 0.170 |
Why?
|
| Consensus | 1 | 2021 | 87 | 0.170 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 69 | 0.170 |
Why?
|
| Patient Admission | 1 | 2021 | 59 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2021 | 41 | 0.170 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2021 | 58 | 0.170 |
Why?
|
| APACHE | 1 | 2020 | 13 | 0.170 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 85 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 412 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 11 | 0.160 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 24 | 0.160 |
Why?
|
| Delirium | 1 | 2020 | 12 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2020 | 64 | 0.160 |
Why?
|
| Decision Making | 1 | 2022 | 202 | 0.160 |
Why?
|
| Comorbidity | 2 | 2019 | 573 | 0.160 |
Why?
|
| Cross Infection | 1 | 2020 | 56 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2020 | 138 | 0.150 |
Why?
|
| Myocardial Infarction | 2 | 2021 | 483 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 17 | 0.150 |
Why?
|
| Patients | 1 | 2019 | 48 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2019 | 63 | 0.150 |
Why?
|
| Kidney Pelvis | 1 | 2018 | 17 | 0.140 |
Why?
|
| Kidney Calculi | 1 | 2018 | 23 | 0.140 |
Why?
|
| Multicystic Dysplastic Kidney | 1 | 2018 | 1 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 881 | 0.140 |
Why?
|
| Cystostomy | 1 | 2018 | 5 | 0.140 |
Why?
|
| Hydronephrosis | 1 | 2018 | 12 | 0.140 |
Why?
|
| Hematuria | 1 | 2018 | 11 | 0.140 |
Why?
|
| Hypertension, Portal | 1 | 2018 | 10 | 0.140 |
Why?
|
| Analgesia | 1 | 2018 | 30 | 0.140 |
Why?
|
| Varicose Veins | 1 | 2018 | 6 | 0.140 |
Why?
|
| Polysomnography | 2 | 2015 | 40 | 0.140 |
Why?
|
| Angiotensin I | 1 | 2020 | 241 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 111 | 0.140 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 64 | 0.140 |
Why?
|
| Equipment Design | 1 | 2018 | 179 | 0.140 |
Why?
|
| Hypoglycemic Agents | 3 | 2009 | 180 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 779 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2021 | 908 | 0.140 |
Why?
|
| Surgical Flaps | 1 | 2018 | 77 | 0.130 |
Why?
|
| Hospitals | 1 | 2018 | 109 | 0.130 |
Why?
|
| Length of Stay | 1 | 2018 | 329 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2018 | 82 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 764 | 0.130 |
Why?
|
| Myocardium | 1 | 2018 | 191 | 0.130 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 67 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 175 | 0.130 |
Why?
|
| Amides | 1 | 2016 | 18 | 0.130 |
Why?
|
| Fentanyl | 1 | 2016 | 32 | 0.130 |
Why?
|
| Nausea | 1 | 2016 | 52 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 99 | 0.130 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1572 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 490 | 0.120 |
Why?
|
| Facial Expression | 1 | 2016 | 4 | 0.120 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 6 | 0.120 |
Why?
|
| Bupivacaine | 1 | 2016 | 52 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 100 | 0.120 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 14 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2018 | 183 | 0.120 |
Why?
|
| Heart Rate | 1 | 2018 | 343 | 0.120 |
Why?
|
| Laparoscopy | 2 | 2015 | 184 | 0.120 |
Why?
|
| Osteoarthritis | 1 | 2016 | 79 | 0.120 |
Why?
|
| Amygdala | 1 | 2016 | 59 | 0.120 |
Why?
|
| Patient Simulation | 1 | 2015 | 29 | 0.120 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 28 | 0.120 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 28 | 0.110 |
Why?
|
| Glycopeptides | 1 | 2015 | 4 | 0.110 |
Why?
|
| beta-Lactams | 1 | 2015 | 7 | 0.110 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 4 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 240 | 0.110 |
Why?
|
| Anesthetics, Intravenous | 2 | 2012 | 16 | 0.110 |
Why?
|
| Blood Gas Analysis | 1 | 2014 | 17 | 0.110 |
Why?
|
| Internationality | 2 | 2025 | 23 | 0.110 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 74 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 26 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 91 | 0.110 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 95 | 0.100 |
Why?
|
| Vitamin D | 1 | 2015 | 189 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 429 | 0.100 |
Why?
|
| Neoplasms | 1 | 2020 | 762 | 0.100 |
Why?
|
| Ohio | 3 | 2020 | 64 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 2 | 2017 | 14 | 0.100 |
Why?
|
| Research Design | 2 | 2025 | 332 | 0.090 |
Why?
|
| Conscious Sedation | 1 | 2012 | 23 | 0.090 |
Why?
|
| Kidney | 1 | 2016 | 523 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 29 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2015 | 324 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 332 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2025 | 308 | 0.090 |
Why?
|
| Electroconvulsive Therapy | 1 | 2011 | 28 | 0.090 |
Why?
|
| Electroencephalography | 1 | 2011 | 72 | 0.090 |
Why?
|
| Seizures | 1 | 2011 | 64 | 0.080 |
Why?
|
| Receptors, Glucagon | 1 | 2009 | 1 | 0.080 |
Why?
|
| Early Diagnosis | 2 | 2020 | 60 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2009 | 43 | 0.080 |
Why?
|
| Dipeptides | 2 | 2005 | 9 | 0.070 |
Why?
|
| Brain | 1 | 2015 | 947 | 0.070 |
Why?
|
| Encephalocele | 1 | 2007 | 2 | 0.070 |
Why?
|
| Proline | 2 | 2005 | 11 | 0.070 |
Why?
|
| Nitriles | 2 | 2005 | 23 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2017 | 41 | 0.070 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2007 | 10 | 0.070 |
Why?
|
| Anesthesia, Inhalation | 1 | 2007 | 16 | 0.070 |
Why?
|
| Prevalence | 2 | 2020 | 1002 | 0.070 |
Why?
|
| Obesity | 1 | 2015 | 1152 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2020 | 180 | 0.060 |
Why?
|
| Rats | 3 | 2005 | 1609 | 0.060 |
Why?
|
| Animals | 6 | 2012 | 7588 | 0.060 |
Why?
|
| Adamantane | 1 | 2005 | 3 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2021 | 338 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 15 | 0.060 |
Why?
|
| Glycine | 1 | 2005 | 27 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2015 | 98 | 0.060 |
Why?
|
| Linear Models | 2 | 2016 | 445 | 0.060 |
Why?
|
| Buffers | 1 | 2025 | 10 | 0.060 |
Why?
|
| Isotonic Solutions | 1 | 2025 | 5 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2025 | 114 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 682 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2015 | 288 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2004 | 19 | 0.050 |
Why?
|
| Neutrophil Activation | 1 | 2003 | 4 | 0.050 |
Why?
|
| Bile | 1 | 2003 | 7 | 0.050 |
Why?
|
| Permeability | 1 | 2003 | 9 | 0.050 |
Why?
|
| Platelet Activating Factor | 1 | 2003 | 14 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2003 | 12 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 163 | 0.050 |
Why?
|
| Intestines | 1 | 2003 | 60 | 0.050 |
Why?
|
| Receptors, Corticotropin | 1 | 2003 | 2 | 0.050 |
Why?
|
| Tyrosine | 1 | 2003 | 23 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 73 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2003 | 141 | 0.050 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 17 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 173 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2003 | 111 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 164 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 69 | 0.050 |
Why?
|
| Adolescent | 3 | 2018 | 3640 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 754 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2021 | 10 | 0.040 |
Why?
|
| Oscillometry | 1 | 2020 | 1 | 0.040 |
Why?
|
| Workplace | 1 | 2021 | 50 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 92 | 0.040 |
Why?
|
| Middle East | 1 | 2020 | 5 | 0.040 |
Why?
|
| Asia | 1 | 2020 | 19 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2020 | 56 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2021 | 186 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 72 | 0.040 |
Why?
|
| Burnout, Professional | 1 | 2021 | 53 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 1307 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 34 | 0.040 |
Why?
|
| Troponin | 1 | 2020 | 109 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 315 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 130 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 565 | 0.040 |
Why?
|
| Neurophysins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2018 | 19 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 194 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 72 | 0.040 |
Why?
|
| Albumins | 1 | 2018 | 44 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 64 | 0.040 |
Why?
|
| Young Adult | 2 | 2018 | 2734 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 2 | 0.040 |
Why?
|
| Enbucrilate | 1 | 2018 | 2 | 0.040 |
Why?
|
| Tissue Adhesives | 1 | 2018 | 7 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 392 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 292 | 0.030 |
Why?
|
| Morbidity | 1 | 2018 | 101 | 0.030 |
Why?
|
| Heart | 1 | 2019 | 185 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 76 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 360 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2017 | 79 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 467 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 2016 | 7 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2016 | 32 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2005 | 1462 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2009 | 186 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 486 | 0.030 |
Why?
|
| Mice | 3 | 2009 | 2527 | 0.030 |
Why?
|
| Warm Ischemia | 1 | 2016 | 9 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 107 | 0.030 |
Why?
|
| Creatinine | 1 | 2016 | 199 | 0.030 |
Why?
|
| Mass Screening | 1 | 2017 | 268 | 0.030 |
Why?
|
| Rats, Zucker | 2 | 2005 | 5 | 0.030 |
Why?
|
| Enterococcus | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 352 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 39 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 43 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 119 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2015 | 43 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 309 | 0.030 |
Why?
|
| Emotions | 1 | 2015 | 59 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2016 | 125 | 0.030 |
Why?
|
| Attention | 1 | 2015 | 82 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 34 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2015 | 159 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 95 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2005 | 78 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2015 | 179 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 69 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 783 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 877 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 363 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 410 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 6 | 0.020 |
Why?
|
| Safety | 1 | 2011 | 77 | 0.020 |
Why?
|
| Stroke | 1 | 2016 | 609 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 281 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2011 | 125 | 0.020 |
Why?
|
| Cricetulus | 1 | 2009 | 13 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2285 | 0.020 |
Why?
|
| CHO Cells | 1 | 2009 | 24 | 0.020 |
Why?
|
| Cricetinae | 1 | 2009 | 39 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2009 | 85 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 695 | 0.020 |
Why?
|
| Dogs | 1 | 2009 | 120 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 287 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 356 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 976 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 622 | 0.020 |
Why?
|
| Occipital Lobe | 1 | 2007 | 5 | 0.020 |
Why?
|
| Corrosion | 1 | 2007 | 2 | 0.020 |
Why?
|
| Arytenoid Cartilage | 1 | 2007 | 2 | 0.020 |
Why?
|
| Calcium Compounds | 1 | 2007 | 9 | 0.020 |
Why?
|
| Oropharynx | 1 | 2007 | 8 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 2007 | 15 | 0.020 |
Why?
|
| Sodium Hydroxide | 1 | 2007 | 6 | 0.020 |
Why?
|
| Anesthetics, Inhalation | 1 | 2007 | 17 | 0.020 |
Why?
|
| Oxides | 1 | 2007 | 18 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2007 | 28 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2007 | 40 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2007 | 47 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2005 | 10 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 20 | 0.010 |
Why?
|
| Biological Availability | 1 | 2005 | 21 | 0.010 |
Why?
|
| Mice, Obese | 1 | 2005 | 23 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2007 | 694 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2005 | 125 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 2004 | 9 | 0.010 |
Why?
|
| Drug Stability | 1 | 2004 | 9 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2004 | 2 | 0.010 |
Why?
|
| Solutions | 1 | 2004 | 36 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2004 | 83 | 0.010 |
Why?
|
| Receptors, Melanocortin | 1 | 2003 | 1 | 0.010 |
Why?
|
| Insulin | 1 | 2005 | 367 | 0.010 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2003 | 4 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2004 | 223 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 160 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 494 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 169 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 115 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 259 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 213 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 536 | 0.010 |
Why?
|